Aortic dissection in a patient treated by sunitinib for metastatic renal cell carcinoma
Authors:
Open Access
- 29 October 2009
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 21 (1) , 186-187
Abstract
The development of antiangiogenic agents targeting the vascular endothelial growth factor (VEGF) pathway (sunitinib, sorafenib, bevacizumab and temsirolimus) has revolutionized the treatment of metastatic renal clear-cell carcinoma. Adverse events attributed to these agents targeting the vascularization include cardiovascular effects. We report here a case of aortic dissection in a patient treated by sunitinib and discuss the cardiovascular toxicity of sunitinib.Keywords
This publication has 5 references indexed in Scilit:
- Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysisThe Lancet Oncology, 2008
- Home Blood-Pressure Monitoring in Patients Receiving SunitinibNew England Journal of Medicine, 2008
- Acute aortic dissection in a hypertensive patient with prostate cancer undergoing chemotherapy containing bevacizumabActa Oncologica, 2008
- Cardiotoxicity associated with tyrosine kinase inhibitor sunitinibThe Lancet, 2007
- Diagnosis and management of patients with aortic dissectionHeart, 2007